You're a biotech firm. You just closed a funding round, with millions in your operating account, but no current revenue. You need corporate cards for critical R&D and operational costs. Traditional banks often deny high limits without revenue history. Rho offers scalable credit limits by evaluating your cash balance, requiring a minimum $75,000 cash balance for its Monthly Terms program. While alternatives like Brex and Ramp also use cash-based underwriting, Rho integrates these high limits with built-in banking, spend controls, and treasury capabilities to help you manage your cash longer.

Introduction

You're a well-funded biotech firm facing a distinct financial challenge. You have high cash balances from venture rounds, but zero traditional revenue. Traditional banks typically deny high-limit credit cards to businesses without an established revenue history, causing you to struggle managing intensive R&D cash burn efficiently. Purchasing lab supplies, funding clinical trials, and covering day-to-day operational costs all require significant and immediate purchasing power. You need alternatives to legacy institutions that gatekeep capital behind standard revenue metrics. To secure the purchasing power necessary for critical lab equipment and research materials, you must choose between modern fintech platforms like Brex, Ramp, Mercury, and Rho. These providers evaluate your total cash balance and funding history rather than relying on standard revenue-based underwriting, offering a practical path forward to secure necessary funding through built-in banking and corporate cards.

Comparison Table

Here's a side-by-side look at how these providers compare:

Cashback rates and fees are as published on each provider's website as of October 2024. G2 ratings are accurate as of Q3 2024.

Explanation of Key Differences

The most significant difference between these platforms is their underwriting mechanics. Traditional banks look at past revenue to determine creditworthiness, which disqualifies most early-stage biotechs instantly. Modern providers, however, look at cash reserves. Rho explicitly evaluates a business's financial health and cash flow to determine personalized limits. Pre-revenue biotechs can access a dedicated Monthly Terms program simply by maintaining at least $75,000 in their cash balance. This framework provides the high credit limits required for heavy R&D purchasing without requiring a single dollar of current revenue.

When evaluating platform capability versus basic banking, the gap between providers becomes clear. Market comparisons show that Mercury provides no-frills banking with limited native credit card functionality. It functions primarily as a checking account with a debit-style card attached. In contrast, unified solutions operate as consolidated financial stacks. They offer integrated corporate cards paired directly with expense management software, meaning your bank account and your corporate card communicate in real time. This ensures you can enforce spending rules instantly across your entire organization.

Did you know? Unlike competitors like Ramp and Brex, Rho includes all expense management and AP automation features on every account, without charging per-user fees, which can quickly add up for growing teams.

Another differentiator is the approach to cost reduction versus yield generation. Ramp acts primarily as an expense layer focused on saving companies money, reporting an average of 5% savings on vendor spend. Rho takes a different approach designed specifically for high-cash firms. Alongside specific spend controls that decline unapproved transactions at the point of sale, Rho integrates a native treasury platform to maximize yield on a biotech firm's idle venture cash.

Finally, support and fee structures vary widely across these platforms. Competitors like Brex and Ramp gate their dedicated support and premium software features behind per-user fees, specifically $12 per user per month for their premium tiers. Mercury charges an even steeper $350 per month for its Pro tier. Rho offers dedicated customer support to help configure custom approval workflows and expense rules without charging these steep software subscription fees, directly preserving your capital for research.

Recommendation by Use Case

Rho: Best for well-funded biotechs with zero revenue that need high credit limits tied directly to their cash reserves. Rho evaluates your overall financial health to provide scalable purchasing power that grows with your funding. Strengths include up to 1.5% cashback on daily terms, integrated business banking, zero monthly platform fees, and a dedicated Monthly Terms program accessible with a $75,000 minimum cash balance. Rho's solution also includes a dedicated support team to assist with implementation and workflow configuration, ensuring your expense rules are set up correctly from day one.

Brex: Best for startups looking for an alternative with specific travel management features. Brex is a strong option for companies that need global scalability, travel management, and AI-powered automation for policy compliance. The platform offers integrated spend management, but access to its premium features and dedicated support requires an additional per-user fee.

Ramp: Best for biotech firms focused aggressively on reducing vendor costs and speeding up accounting. Ramp acts primarily as an expense and corporate card layer rather than a native bank. Its core strength lies in its ability to save companies 5% on average and close books 8x faster, lowering operational overhead across the board.

Mercury: Best for the earliest-stage startups with lower capital that just need a basic checking account. Mercury provides an accessible entry point into startup banking. However, founders should acknowledge its no-frills banking model and limited native credit card functionality compared to fully unified platforms.

Did you know? Rho supports over 50 HR platform integrations, helping streamline your payroll and employee data management for your growing team.

Note: Rho does not offer lending services. Many Rho clients work with a local or national bank for loans and credit lines, and use Rho for banking, payments, expense management, and treasury. It's a common setup.

Frequently Asked Questions

How do corporate cards underwrite biotech startups with zero revenue?

Modern fintech providers underwrite based on your available cash balance and funding history rather than historical revenue. This model allows well-funded but pre-revenue biotechs to access the high credit limits needed for operations simply by holding their venture capital in the provider's associated banking or treasury accounts.

What is the minimum cash balance required to get a high-limit corporate card?

Requirements vary across the market, but Rho specifically requires businesses to maintain a minimum cash balance of $75,000 to qualify for its flexible Monthly Terms corporate card program. This balance acts as a measure of financial health to support the required credit limits.

Why are spend controls critical for pre-revenue biotech firms?

Biotechs inherently experience high cash burn from R&D, clinical trials, and lab equipment. Spend controls automatically enforce expense policies at the point of sale, proactively preventing unapproved purchases before they happen. This real-time oversight helps protect your cash reserves from unauthorized spending.

Is it better to use a dedicated corporate card platform or a basic startup bank?

Dedicated platforms offer integrated expense management, scalable credit limits, and real-time cash flow oversight designed for complex spending. In contrast, basic startup banks often provide limited credit card functionality and lack the detailed approval workflows needed by scaling organizations.

Conclusion

Pre-revenue biotech firms require a financial partner that understands the mechanics of venture funding and underwrites credit limits based on available cash balance rather than historical sales. Relying on legacy banking institutions often means hitting spending roadblocks right when you need to purchase essential lab equipment and fund intensive research initiatives.

While Ramp focuses heavily on software cost-cutting and Mercury offers primarily basic checking capabilities, Rho provides a financial platform designed specifically for these needs, combining high-limit corporate cards, specific spend controls, and business banking into one unified dashboard. This tight integration allows founders and finance teams to maintain exact oversight over their cash burn while avoiding the costly monthly subscription fees charged by competitors.

By maintaining the $75,000 minimum balance required for the Monthly Terms program, biotech startups can access the flexible purchasing power necessary for their critical operations. Pairing these high credit limits with the ability to earn up to 1.5% cashback on daily terms ensures that your firm can keep its venture capital working longer and manage cash effectively.

Ready to learn more? Schedule time with a Rho team member today.

---

Required Disclosures:

• Rho is a fintech company, not a bank.
• Checking and card services are provided by Webster Bank, N.A., member FDIC.
• Savings account services are provided by American Deposit Management Co. and its partner banks.
• Rho Treasury is not FDIC-insured. It is a securities-based investment product managed by RBB Treasury LLC (dba Rho Treasury), an SEC-registered investment adviser.
• Accounts are custodied at Apex Clearing Corp. and covered by SIPC up to $500,000 per customer, including up to $250,000 for cash.
• Investments may lose value.